We use cookies to provide you with a better experience. By continuing to browse the site you are agreeing to our use of cookies in accordance with our Cookie Policy.
The Indian government is considering setting up a vaccine manufacturers council in the country in order to promote the manufacture and export of vaccines.
Savient Pharmaceuticals, Inc. (NASDAQ: SVNT), a specialty pharmaceutical company dedicated to developing, manufacturing and marketing novel therapeutic products that address unmet medical needs, announced today that the United States District Court for the District of New Jersey dismissed, without prejudice, the Consolidated
Amended Class Action Complaint filed on December 20, 2002 against the Company and three of its officers.
Viventia Biotech Inc. (TSX:VBI) today announced that its board of directors has ratified two interim bridge loans, for $900,000 and $2 million obtained on July 26, 2005 and August 3, 2005 respectively, from Mr. Leslie Dan, the Company's Chairman and an entity controlled by him. In addition, the Board of Directors approved and authorized the Company to obtain an additional interim bridge loan of $400,000 from Mr. Dan to fund ongoing operations.
The European Medicines Agency (EMEA) has launched a six-month consultation period on a draft guideline on the conduct of pharmacovigilance for medicines used by the paediatric population, children from birth to 18 years of age.
Bolder BioTechnology, Inc. today announced that it has been awarded a $121,844 Phase I Small Business Innovation Research (SBIR) grant from the National Cancer Institute of The National Institutes of Health.
Protein Design Labs, Inc. (PDL) (Nasdaq: PDLI -- News) announced today that the Form S-3 Registration Statement filed in connection with the 2.00% Convertible Senior Notes due 2012 in an aggregate amount of $250.0 million has been declared effective by the U.S. Securities and Exchange Commission.
The cost of health services in South Africa will rise rapidly over the next few years owing to the impact of HIV/AIDS, according to researchers from the Health Economics and HIV/AIDS Research Division (HEARD) at the University of KwaZulu-Natal.